Physician profile
Michael S Langan
NPI 1770618688
$14,348.18
in general payments reported to CMS, 2019-2025
67 companies · $2,580 in 2025
The $2,580 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $690 · 2021: $2,375 · 2022: $2,470 · 2023: $2,961 · 2024: $3,272 · 2025: $2,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,813.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,990.72 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,698.38 | 2021-2025 | |
| Lilly USA, LLC | $1,134.22 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $836.82 | 2020-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $810.03 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $652.17 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $570.91 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $570.22 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.16 | 2020-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $479.31 | 2020-2025 | |
| Abbott Laboratories | $466.53 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $360.20 | 2020-2025 | |
| Exact Sciences Corporation | $334.38 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $308.67 | 2022-2024 | |
| Amneal Pharmaceuticals LLC | $245.53 | 2022-2025 | Unithroid |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $233.80 | 2022-2024 | Belsomra, Gardasil 9, Steglatro |
| Corcept Therapeutics | $192.43 | 2023-2024 | Korlym |
| Radius Health, INC. | $185.90 | 2023-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.18 | 2020-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $170.91 | 2020-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $137.85 | 2022 | |
| Cequr Corporation | $133.75 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $130.29 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $127.43 | 2020-2025 | Camzyos, Eliquis |
| Dexcom, INC. | $123.04 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $115.82 | 2020-2023 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $113.95 | 2021-2025 | Nexletol |
| Medtronic, INC. | $98.47 | 2024-2025 | Minimed 780g, Inceptiv |
| Kowa Pharmaceuticals America, INC. | $77.99 | 2020-2022 | |
| Ascendis Pharma Endocrinology INC | $75.53 | 2025 | Yorvipath |
| Actelion Pharmaceuticals US, INC. | $74.16 | 2024-2025 | Opsumit, Uptravi |
| Depuy Synthes Sales INC. | $65.81 | 2025 | Trumatch |
| Sanofi Pasteur INC. | $64.79 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $63.06 | 2021-2022 | |
| Ibsa Pharma INC. | $62.65 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $62.10 | 2021 | |
| Qol Medical, LLC | $55.19 | 2023-2024 | Sucraid, Sucraid |
| Amarin Pharma, INC. | $55.17 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $52.89 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $52.49 | 2025 | Bodyguardian |
| Allergan, INC. | $44.39 | 2020-2021 | |
| Sequel Med Tech, LLC | $43.27 | 2025 | Twiist |
| Axsome Therapeutics, INC. | $40.79 | 2024 | Auvelity |
| Edwards Lifesciences Corporation | $37.63 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $37.28 | 2021-2024 | Crysvita |
| Clarus Therapeutics INC. | $33.34 | 2021 | |
| Idorsia Pharmaceuticals US INC | $31.86 | 2022-2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $31.22 | 2024-2025 | Strensiq |
| Corium, LLC | $29.84 | 2025 | Azstarys |
| Tempus Ai, INC | $25.73 | 2024 | |
| Sumitomo Pharma America, INC. | $23.90 | 2023 | Gemtesa |
| Lucid Diagnostics INC. | $22.47 | 2022 | |
| Recordati_rare_diseases_inc. | $19.80 | 2025 | Isturisa |
| Jazz Pharmaceuticals INC. | $19.48 | 2020 | |
| Ascensia Diabetes Care US INC. | $19.17 | 2025 | |
| Dynavax Technologies Corporation | $18.04 | 2022 | |
| Teleflex LLC | $17.78 | 2023 | Urolift |
| Takeda Pharmaceuticals U.S.A., INC. | $17.05 | 2021 | |
| Irhythm Technologies, INC. | $17.01 | 2024 | Zio Xt Patch, Zio Monitor |
| Zealand Pharma US, INC. | $16.95 | 2021 | |
| Amryt Pharma Holdings LTD | $15.57 | 2023 | Mycapssa |
| Ars Pharmaceuticals Operations, INC. | $15.01 | 2025 | Neffy |
| Kyowa Kirin, INC. | $14.58 | 2023 | Crysvita |
| Shield Therapeutics INC | $14.30 | 2025 | |
| Endo Pharmaceuticals INC. | $14.05 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $13.56 | 2025 | Rhythm Express |
| Chiesi USA, INC. | $13.21 | 2024 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Langan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.